Loading...
Market
Hyrimoz Over 50% Market Share by End of 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Quarterly financial reports from CVS Health and industry market share reports
Story
CVS Health Replaces Humira with Hyrimoz on April 1, Biosimilar Market Share Surges to 36%
Apr 16, 2024, 02:25 PM
Following a strategic decision by CVS Health, credited by analysts including Elizabeth Anderson from Evercore ISI, there has been a significant increase in the prescription rates of biosimilar versions of Humira, specifically Hyrimoz. CVS Health removed Humira from its major commercial formularies on April 1st and replaced it with Hyrimoz, a biosimilar jointly marketed by its subsidiary Cordavis. This change led to a surge in new prescriptions for Hyrimoz, with the market share of biosimilar versions of Humira jumping from 5% to 36% in just the first week of April.
View original story
Similar markets
Less than 20% • 20%
20% to 35% • 20%
36% to 50% • 20%
51% to 65% • 20%
More than 65% • 20%
Decrease by more than 10% • 25%
Decrease by less than 10% • 25%
Remain stable • 25%
Increase • 25%
Under 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Ozempic gains over 30% market share • 25%
Ozempic gains 10-30% market share • 25%
Ozempic gains less than 10% market share • 25%
Ozempic loses market share • 25%
Yes • 50%
No • 50%
Top 10% • 25%
Top 25% • 25%
Top 50% • 25%
Below 50% • 25%
Significant increase • 33%
Moderate increase • 34%
No change • 33%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30%+ • 25%
Increase by over 50% • 25%
Increase by 20-50% • 25%
Increase by less than 20% • 25%
Decrease • 25%
Amgen's Bkemv dominates • 33%
AstraZeneca retains majority market share • 33%
Other competitors gain significant market share • 34%